Boston Scientific Tries To Climb Back Up From ICD Market Share Spill
This article was originally published in The Gray Sheet
Executive SummaryBoston Scientific is banking on intense communication with physicians and new product launches to eventually pull its ICD business back to its pre-sales-suspension standing, but the firm acknowledges that it will be playing catch-up for the foreseeable future
You may also be interested in...
St. Jude Medical has issued a warning about premature battery depletion issues in some ICDs, but says it has already fixed the problem. Analysts say it is not likely to have any impact on Abbott’s plans to acquire St. Jude by the end of 2016.